New strategies in AML: checkpoint inhibitors combined with T-cell engagers
The spliceosome mutations that can cause hematological malignancies
Progession of AML treatment over the past decades
Highlights from EHA 2016 press briefings: POLLUX and EURO-SKI trials and BiTE antibodies
T-cell engaging antibodies: what lessons have we learnt?